Should I buy or sell argenx stock right now?

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last twelve months. There are currently 1 sell rating, 2 hold ratings, 16 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARGX shares. View ARGX analyst ratings or view top-rated stocks .

What is argenx's stock price target for 2024?

20 Wall Street research analysts have issued 12 month target prices for argenx's shares. Their ARGX share price targets range from $435.00 to $628.00. On average, they expect the company's stock price to reach $547.05 in the next twelve months. This suggests a possible upside of 24.9% from the stock's current price. View analysts price targets for ARGX or view top-rated stocks among Wall Street analysts .

How have ARGX shares performed in 2023?

argenx's stock was trading at $378.83 at the beginning of 2023. Since then, ARGX stock has increased by 15.6% and is now trading at $438.07. View the best growth stocks for 2023 here .

When is argenx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024. View our ARGX earnings forecast .

How were argenx's earnings last quarter?

argenx SE (NASDAQ:ARGX) posted its quarterly earnings data on Tuesday, October, 31st. The company reported ($1.25) earnings per share for the quarter, topping analysts' consensus estimates of ($1.48) by $0.23. The company earned $339.84 million during the quarter, compared to analysts' expectations of $310.06 million. argenx had a negative trailing twelve-month return on equity of 12.40% and a negative net margin of 22.70%. During the same period in the previous year, the company earned ($4.26) EPS.

What ETFs hold argenx's stock?

ETFs with the largest weight of argenx (NASDAQ:ARGX) stock in their portfolio include VanEck Biotech ETF (BBH) , First Trust NYSE Arca Biotechnology Index Fund (FBT) , Fidelity Disruptive Medicine ETF (FMED) , BlackRock Future Health ETF (BMED) , AdvisorShares Dorsey Wright ADR ETF (AADR) , Simplify Health Care ETF (PINK) , American CenturyFocused Dynamic Growth ETF (FDG) and iShares Biotechnology ETF (IBB) .

What other stocks do shareholders of argenx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG) , Kohl's (KSS) , AcelRx Pharmaceuticals (ACRX) , Gilead Sciences (GILD) , Neurocrine Biosciences (NBIX) , Pfizer (PFE) , CRISPR Therapeutics (CRSP) , Fate Therapeutics (FATE) , NVIDIA (NVDA) and Sarepta Therapeutics (SRPT) .

(ARGX) raised $65 million in an initial public offering on Thursday, May 18th 2017. The company issued 3,600,000 shares at $18.18 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are argenx's major shareholders?

argenx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (8.40%), Artisan Partners Limited Partnership (4.79%), Jennison Associates LLC (2.56%), Massachusetts Financial Services Co. MA (0.98%), Morgan Stanley (0.94%) and RTW Investments LP (0.86%).

How do I buy shares of argenx?

Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

argenx Stock Price, News & Analysis (NASDAQ:ARGX)

$435.79

-9.55 (-2.14%)

(As of 04:30 PM ET)

Compare

Today's Range: $435.24
▼
$444.78
50-Day Range: $445.34
▼
$514.01
52-Week Range: $333.07
▼
$550.76

Volume: 413,121 shs
Average Volume: 250,614 shs
Market Capitalization: $25.75 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $547.11

argenx MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.79 Rating Score
Upside/Downside: 24.9% Upside
$547.05 Price Target
Short Interest: Healthy
1.41% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.52
Based on 21 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.76) to ($2.76) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

819th out of 949 stocks

Biological Products, Except Diagnostic Industry

142nd out of 161 stocks

3.4

Analyst's Opinion

Consensus Rating
argenx has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 16 buy ratings, 2 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $547.05, argenx has a forecasted upside of 24.9% from its current price of $438.07.
Amount of Analyst Coverage
argenx has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
1.41% of the outstanding shares of argenx have been sold short.
Short Interest Ratio / Days to Cover
argenx has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in argenx has recently increased by 4.63%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
argenx does not currently pay a dividend.
Dividend Growth
argenx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ARGX.

2.0

News and Social Media Coverage

News Sentiment
argenx has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 21 news articles for argenx this week, compared to 4 articles on an average week.
Search Interest
Only 1 people have searched for ARGX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added argenx to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, argenx insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.43% of the stock of argenx is held by insiders.
Percentage Held by Institutions
52.77% of the stock of argenx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for argenx are expected to grow in the coming year, from ($4.76) to ($2.76) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of argenx is -105.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of argenx is -105.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
argenx has a P/B Ratio of 8.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About argenx Stock (NASDAQ:ARGX)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

ARGX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ARGX Stock News Headlines

November 29, 2023 | markets.businessinsider.com

Analyst Ratings for argenx

November 29, 2023 | benzinga.com

argenx Stock (NASDAQ:ARGX), Analyst Ratings, Price Targets, Predictions

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 29, 2023 | markets.businessinsider.com

Maintaining Buy Rating on Argenx: Confidence in Efgartigimod’s Prospects Despite Phase 3 Setback

November 28, 2023 | msn.com

These 2 Stocks Are Falling in a Fading Rally

November 28, 2023 | bizjournals.com

Argenx drug meets surprise late-stage failure

November 28, 2023 | markets.businessinsider.com

Why Is Dutch Pharma Argenx Trading Lower Today?

November 28, 2023 | finanznachrichten.de

argenx SE: argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 28, 2023 | marketwatch.com

Argenx Shares Down After Vyvgart Study Misses Primary Endpoint

November 28, 2023 | markets.businessinsider.com

Argenx's VYVGART Hytrulo Trial In Primary Immune Thrombocytopenia Fails To Meet Key Goals

November 28, 2023 | finance.yahoo.com

argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

November 27, 2023 | seekingalpha.com

argenx Q3: Navigating The Highs And Hurdles Of A Market Odyssey (Rating Upgrade)

November 27, 2023 | msn.com

Argen X SE - ADR (ARGX) Price Target Increased by 6.07% to 598.01

November 26, 2023 | morningstar.com

argenx SE ARGX

November 19, 2023 | americanbankingnews.com

argenx SE (NASDAQ:ARGX) Given Average Recommendation of "Moderate Buy" by Analysts

November 16, 2023 | markets.businessinsider.com

Argenx Announces EC Approval For Subcutaneous Vyvgart For Generalized Myasthenia Gravis

November 16, 2023 | finanznachrichten.de

argenx SE: argenx Announces European Commission Approval of Subcutaneous VYVGART (efgartigimod alfa) for Generalized Myasthenia Gravis

November 16, 2023 | finance.yahoo.com

argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis

November 16, 2023 | finance.yahoo.com

argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis

November 7, 2023 | insidermonkey.com

Here’s Why You Should Consider Investing in Argenx SE (ARGX)

November 3, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: IQVIA Holdings (IQV), Idexx Laboratories (IDXX) and Argenx Se (ARGX)

November 1, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), Argenx Se (ARGX) and Theratechnologies (THTX)

November 1, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: GE Healthcare Technologies Inc (GEHC), Argenx Se (ARGX)

November 1, 2023 | finanznachrichten.de

argenx SE: argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

November 1, 2023 | finance.yahoo.com

argenx SE (NASDAQ:ARGX) Q3 2023 Earnings Call Transcript

November 1, 2023 | markets.businessinsider.com

argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

See More Headlines

Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/31/2023
Today: 11/29/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/07/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ARGX
CUSIP: N/A
CIK: 1697862
Web: www.argenx.com
Phone: (176) 303-0488
Fax: N/A
Employees: 843
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $547.11
High Stock Price Target: $628.00
Low Stock Price Target: $435.00
Potential Upside/Downside: +22.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.79
Research Coverage: 19 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.16)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-709,590,000.00
Net Margins: -22.70%
Pretax Margin: -52.69%
Return on Equity: -12.40%
Return on Assets: -11.12%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.47
Quick Ratio: 7.84

Sales & Book Value

Annual Sales: $445.27 million
Price / Sales: 59.09
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $50.79 per share
Price / Book: 8.77

Miscellaneous

Outstanding Shares: 59,080,000
Free Float: 57,643,000
Market Cap: $26.31 billion
Optionable: Optionable
Beta: 0.79

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Timothy Van Hauwermeiren EMBA (Age 51)
M.B.A., M.Sc., CEO & Executive Director
Comp: $1.44M
Mr. Karl Gubitz (Age 53)
Chief Financial Officer
Ms. Malini Moorthy (Age 53)
General Counsel
Mr. Arjen Lemmen M.Sc. (Age 38)
Vice President of Corporate Development & Strategy
Ms. Andria Wilk (Age 49)
Global Head of Quality
Mr. Luc Truyen (Age 58)
Chief Medical Officer
Ms. Karen Massey (Age 44)
Chief Operating Officer
Mr. Filip Borgions
VP & Global Head of Technical Operations
Mr. Peter Ulrichts (Age 43)
Chief Scientific Officer
Ms. Beth DelGiacco
VP and Global Head of Corporate Communications & Investor Relations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

Should I Buy argenx Stock? ARGX Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of argenx was last updated on Thursday, November 16, 2023 at 12:00 AM.

Pros

Here are some ways that investors could benefit from investing in argenx SE:

argenx SE is a biotechnology company that develops therapies for the treatment of autoimmune diseases, which is a growing market with high demand.
Recent developments in argenx SE's therapies have shown promising results in clinical trials, indicating potential for successful treatments.
argenx SE has formed strategic partnerships with major pharmaceutical companies, such as AbbVie and Janssen, which can provide financial support and expertise in drug development.
The company has a strong pipeline of innovative therapies in various stages of development, offering potential for future revenue growth.
argenx SE has a collaboration with IQVIA Holdings Inc. to provide safety systems and services, ensuring the safety and quality of its therapies.

Cons

Investors should be bearish about investing in argenx SE for these reasons:

Investing in biotechnology companies carries inherent risks, including the possibility of clinical trial failures or regulatory setbacks.
The competitive landscape in the biotechnology industry is intense, with many companies vying for market share and limited resources.
argenx SE's success heavily relies on the successful development and commercialization of its therapies, which may face challenges in the highly regulated healthcare industry.
Fluctuations in the stock market and investor sentiment can impact the stock price of argenx SE, potentially leading to volatility in investment returns.
Investors should carefully consider their risk tolerance and conduct thorough research before making investment decisions in argenx SE.

ARGX Stock Analysis - Frequently Asked Questions

Should I buy or sell argenx stock right now?: 20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last twelve months. There are currently 1 sell rating, 2 hold ratings, 16 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARGX shares.
View ARGX analyst ratings or view top-rated stocks.
What is argenx's stock price target for 2024?: 20 Wall Street research analysts have issued 12 month target prices for argenx's shares. Their ARGX share price targets range from $435.00 to $628.00. On average, they expect the company's stock price to reach $547.05 in the next twelve months. This suggests a possible upside of 24.9% from the stock's current price.
View analysts price targets for ARGX or view top-rated stocks among Wall Street analysts.
How have ARGX shares performed in 2023?: argenx's stock was trading at $378.83 at the beginning of 2023. Since then, ARGX stock has increased by 15.6% and is now trading at $438.07.
View the best growth stocks for 2023 here.
When is argenx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our ARGX earnings forecast.
How were argenx's earnings last quarter?: argenx SE (NASDAQ:ARGX) posted its quarterly earnings data on Tuesday, October, 31st. The company reported ($1.25) earnings per share for the quarter, topping analysts' consensus estimates of ($1.48) by $0.23. The company earned $339.84 million during the quarter, compared to analysts' expectations of $310.06 million. argenx had a negative trailing twelve-month return on equity of 12.40% and a negative net margin of 22.70%. During the same period in the previous year, the company earned ($4.26) EPS.
What ETFs hold argenx's stock?: ETFs with the largest weight of argenx (NASDAQ:ARGX) stock in their portfolio include VanEck Biotech ETF (BBH), First Trust NYSE Arca Biotechnology Index Fund (FBT), Fidelity Disruptive Medicine ETF (FMED), BlackRock Future Health ETF (BMED), AdvisorShares Dorsey Wright ADR ETF (AADR), Simplify Health Care ETF (PINK), American CenturyFocused Dynamic Growth ETF (FDG) and iShares Biotechnology ETF (IBB).

What other stocks do shareholders of argenx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).
When did argenx IPO?: (ARGX) raised $65 million in an initial public offering on Thursday, May 18th 2017. The company issued 3,600,000 shares at $18.18 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are argenx's major shareholders?: argenx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (8.40%), Artisan Partners Limited Partnership (4.79%), Jennison Associates LLC (2.56%), Massachusetts Financial Services Co. MA (0.98%), Morgan Stanley (0.94%) and RTW Investments LP (0.86%).
How do I buy shares of argenx?: Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ARGX) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

argenx Stock Price, News & Analysis (NASDAQ:ARGX)

argenx MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About argenx Stock (NASDAQ:ARGX)

ARGX Stock Price History

ARGX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

Should I Buy argenx Stock? ARGX Pros and Cons Explained

Pros

Cons

ARGX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™